Fig 1.
Selection of eligible patients with metastatic or recurrent non-small cell lung cancer from the database.
NSCLC, non–small-cell lung cancer; PD-L1, programmed death-ligand 1. aAll testing for PD-L1 was required to be on or after October 2, 2015; however, patients were not required to have a PD-L1 test to be eligible for the study.
Table 1.
Baseline demographic and clinical characteristics of patients with metastatic or recurrent NSCLC by PD-L1 testing status.
Table 2.
PD-L1 biomarker immunohistochemical (IHC) assay results by assay typea.
Table 3.
PD-L1 testing trends over time, by assay type.